BiotechTube
Astra Biotech

Astra Biotech

Pre-clinical
Berlin, GermanyFounded 2009astrabiotech.com

Astra Biotech is a privately-held diagnostics company based in Berlin, Germany, with a mission to optimize patient healthcare through innovative, IVD-compliant assays that enable personalized medicine. The company holds ISO 13485 certification since 2011 and has achieved major IVDR milestones, underscoring its commitment to quality. Its strategic direction involves global expansion, as evidenced by its participation in MEDICA 2025, and a focus on developing tests for inherited diseases and drug sensitivity to support tailored therapies.

Market Cap
Private
Pipeline
—
Patents
—
Publications
—

Private Company

Total funding raised: $13.8M

AI Company Overview

Astra Biotech is a privately-held diagnostics company based in Berlin, Germany, with a mission to optimize patient healthcare through innovative, IVD-compliant assays that enable personalized medicine. The company holds ISO 13485 certification since 2011 and has achieved major IVDR milestones, underscoring its commitment to quality. Its strategic direction involves global expansion, as evidenced by its participation in MEDICA 2025, and a focus on developing tests for inherited diseases and drug sensitivity to support tailored therapies.

Infectious DiseasesOncologyAllergyGenetic DisordersEndocrinology

Technology Platform

Diagnostic assays based on established ELISA (enzyme-linked immunosorbent assay) and qPCR (quantitative polymerase chain reaction) technologies, with a focus on high sensitivity, specificity, and IVD compliance.

Funding History

2
Total raised:$13.8M
Series A$12MNov 15, 2022
Seed$1.8MSep 15, 2020

Opportunities

Growth is driven by the expanding global IVD market, particularly in personalized medicine (drug sensitivity, genetic disorders) and infectious disease testing.
Achieving IVDR compliance ahead of competitors creates a market advantage in Europe, while the OEM partnership model offers scalable distribution.
Participation in international trade shows like MEDICA supports global expansion goals.

Risk Factors

Key risks include the significant regulatory and cost burden of maintaining EU IVDR compliance, intense competition from large diagnostics corporations that can exert pricing pressure, and potential reliance on a limited number of key products or OEM partners.
The pace of technological change in diagnostics also requires continuous R&D investment to avoid obsolescence.

Competitive Landscape

Astra Biotech competes with large, diversified diagnostics firms (Roche, Abbott, Siemens) and smaller European specialty IVD companies. Its differentiation is based on being a specialist with high-quality, certified assays, a dual sales channel (direct & OEM), and agility in serving niche applications within personalized medicine and specific infectious diseases like Chlamydia.